GSK plc filed a Form 6-K on November 18, 2026, announcing that the U.S. Food and Drug Administration granted accelerated approval to Nelkarmi (neladalkib) for adults with previously treated locally advanced or metastatic ALK-positive non-small cell lung cancer.
Key Highlights
- Accelerated approval granted: The FDA approved Nelkarmi (neladalkib) ahead of the original target action date of November 27, 2026.
- ALKOVE-1 trial data: In patients previously treated with alectinib as their only prior ALK TKI, the confirmed overall response rate (ORR) was 49% (33/67; 95% CI: 37%, 62%).
- Second patient group ORR: In patients with two or more prior ALK TKIs and chemotherapy, the ORR was 32% (50/155; 95% CI: 24%, 40%).
- Intracranial activity: Among patients with measurable CNS metastases, intracranial ORR was 55% (11/20; 95% CI: 32%, 77%) in the alectinib-only prior TKI group, including 25% complete responses.
- Safety profile: Permanent discontinuation due to adverse reactions occurred in 5% of patients, with hepatotoxicity the most frequent cause.
- Nuvalent acquisition origin: Nelkarmi is described as part of the portfolio from the recent acquisition of Nuvalent, Inc., according to the filing.
- Second lung cancer approval this year: The filing states this is GSK's second approval in lung cancer in 2026, following Jideytro (zidesamtinib) in July 2026.
FDA Grants GSK Accelerated Approval for Nelkarmi in ALK-Positive NSCLC
According to the filing, the FDA's accelerated approval covers adults with locally advanced or metastatic ALK-positive NSCLC who have previously received one prior ALK tyrosine kinase inhibitor (TKI) consisting of alectinib, or two or more prior ALK TKIs and platinum-based chemotherapy in the unresectable locally advanced or metastatic setting. The approval came before the original FDA target action date of November 27, 2026, and follows the FDA's Breakthrough Therapy and Orphan Drug designations for the drug.
The approval is based on results from ALKOVE-1 (NCT05384626), described in the filing as a global single-arm phase I/II trial. The primary efficacy analysis supporting approval included 222 patients with previously treated ALK-positive NSCLC. For the alectinib-only prior TKI group, duration of response (DOR) of six or more months was observed in 76% of responders and 12 or more months in 52% of responders. In the two-or-more prior ALK TKIs and chemotherapy group, DOR of six or more months was seen in 69% of responders and 12 or more months in 51% of responders, as assessed by blinded independent central review.
The filing reports the most common adverse reactions occurring in 20% or more of patients were hepatotoxicity, musculoskeletal pain, constipation, dysgeusia, peripheral neuropathy, edema, and fatigue. The filing also notes that Nelkarmi is being evaluated in ALKAZAR, an ongoing phase III trial in TKI-naive ALK-positive NSCLC, and in other solid tumours. GSK plc is listed on LSE/NYSE:GSK. The company cautions that forward-looking statements in the announcement are subject to risks and uncertainties, as described in its Annual Report on Form 20-F for 2025 and its Q3 Results for 2026.
What Was Disclosed
GSK plc disclosed the FDA accelerated approval of Nelkarmi (neladalkib) for pretreated ALK-positive NSCLC, supported by ORR and DOR data from the ALKOVE-1 phase I/II trial, along with the drug's safety profile and ongoing phase III evaluation.




Please wait processing your request...